Stoke Therapeutics Inc

Stoke Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines to address severe genetic disorders. Central to their approach is the proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which enhances the production of functional proteins from healthy genes to compensate for defective or non-functioning gene copies. Initially targeting diseases caused by haploinsufficiency, where one gene copy is mutated while the other remains functional, Stoke's TANGO technology has demonstrated the ability to increase full-length protein expression across various healthy genes. This innovative method holds the potential to offer new therapeutic options for a range of genetic conditions that currently have limited treatment alternatives.